How Pharma Cash Colors Operation Warp Speed

April 16 was a big day for Moderna, a Massachusetts biotech company on the verge of becoming a front-runner in the U.S. government’s race for a coronavirus vaccine. It had received roughly half a billion dollars in federal funding to develop a COVID shot that might be used on millions of Americans. Thirteen days after the massive infusion of federal cash—which triggered a jump in the company’s stock price—Moncef Slaoui, a Moderna board member…